Karyopharm Therapeutics Inc. (KPTI)
| Market Cap | 44.65M +28.7% |
| Revenue (ttm) | 151.12M +6.3% |
| Net Income | -194.97M |
| EPS | -14.19 |
| Shares Out | 22.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 458,799 |
| Open | 1.960 |
| Previous Close | 1.950 |
| Day's Range | 1.910 - 1.990 |
| 52-Week Range | 1.800 - 10.990 |
| Beta | 0.95 |
| Analysts | Buy |
| Price Target | 6.40 (+224.87%) |
| Earnings Date | Aug 14, 2026 |
About KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom... [Read more]
Financial Performance
In 2025, Karyopharm Therapeutics's revenue was $146.07 million, an increase of 0.57% compared to the previous year's $145.24 million. Losses were -$196.04 million, 156.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price target is $6.4, which is an increase of 224.87% from the latest price.
News
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Aug. 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company g...
Karyopharm price target lowered to $11 from $14 at Jefferies
Jefferies lowered the firm’s price target on Karyopharm (KPTI) to $11 from $14 and keeps a Buy rating on the shares. The company’s latest update is “mixed to slightly negative”…
Karyopharm price target lowered to $7 from $16 at Piper Sandler
Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on Karyopharm (KPTI) to $7 from $16 and keeps an Overweight rating on the shares. The Phase III XPORT-EC-042 trial…
Karyopharm downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Robert Burns downgraded Karyopharm (KPTI) to Neutral from Buy with a price target of $3, down from $13. The XPORT-EC-042 primary endpoint miss weighs on Karyopharm’s investment...
Karyopharm downgraded to Neutral from Outperform at Baird
Baird downgraded Karyopharm (KPTI) to Neutral from Outperform with a price target of $3, down from $15. The company’s data from the Phase 3 XPORT-EC-042 study evaluating selinexor as a…
Karyopharm down 69% after XPORT-EC-042 trial did not meet primary endpoint
18:19 EDT Karyopharm (KPTI) down 69% after XPORT-EC-042 trial did not meet primary endpoint
Karyopharm to submit sNDA for selinexor plus ruxolitinib
Karyopharm (KPTI) Therapeutics announced that it plans to submit a supplemental New Drug Application to the U.S. FDA in August 2026 seeking accelerated approval of selinexor in combination with ruxoli...
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint
Karyopharm (KPTI) announced topline results from its Phase 3 XPORT-EC-042 trial evaluating selinexor as a maintenance-only therapy compared to placebo in adult patients with TP53 wild-type advanced or...
Karyopharm trading halted, news pending
16:01 EDT Karyopharm (KPTI) trading halted, news pending
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review – – Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data a...
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
– The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) – – A Trend Favoring the Selinexor Arm was Observed with a 5.3 Month Improvement in Median PFS Relative to the Placebo ...
Karyopharm sinks after revealing executive cash retention program
Shares of Karyopharm (KPTI) are trading lower after the company on Friday night disclosed that its board implemented a retention program for certain employees. “The purpose of the 2026 Leadership…
RBC says Karyopharm weakness after compensation plan a buying opportunity
RBC Capital notes Karyopharm (KPTI) shares are down 28% today after the company updated their incentive compensation plan on Friday after the close, adding that the firm has received a…
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company g...
Karyopharm Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Significant progress reported in myelofibrosis and endometrial cancer programs, with phase III SENTRY data showing strong efficacy and survival signals in myelofibrosis and EC-042 readout expected mid-year. Regulatory and commercial strategies are in place, with cash runway into late Q3.
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will parti...
Karyopharm Therapeutics Transcript: Study result
The phase III SENTRY trial showed selinexor plus ruxolitinib significantly improved spleen volume reduction and provided an early survival benefit in JAK inhibitor-naive myelofibrosis patients, with manageable safety and consistent efficacy across subgroups. SVR35 correlated with survival, and the combination may address real-world dosing challenges.
Karyopharm Therapeutics Press release: Study result
Karyopharm Therapeutics issued a press release on June 2, 2026, disclosing material business information to investors.
Karyopharm Therapeutics Slides: Study result
Karyopharm Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Karyopharm says Phase 3 SENTRY trial selected for presentation at EHA 2026
Karyopharm (KPTI) Therapeutics announced that its late-breaking abstract was accepted for an oral presentation at the 2026 European Hematology Association Congress, taking place June 11 to 14 in Stock...
Karyopharm’s selinexor combination shows efficacy in myelofibrosis
Karyopharm (KPTI) will present the results of its Phase 3 SENTRY trial in a presentation at the 2026 ASCO Annual Meeting. The SENTRY results were also published this morning in…
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
– New Data will Highlight a Post-Hoc Analysis from Phase 1 Portion of SENTRY Trial that Indicates Achievement of SVR35 with Selinexor plus Ruxolitinib May Predict Overall Survival – – Selected by EHA'...
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achieving SVR35 at Week 24, versus Ruxolitinib, with a Consistent SVR35 Benefit Observed Across Prespecif...
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial – – Conference Call Scheduled for Tuesday, June 2, 2026 at 2:00 p.m. ET – NEWTON, Mass.